Wu Hong, Zheng Weihong, Eram Mohammad S, Vhuiyan Mynol, Dong Aiping, Zeng Hong, He Hao, Brown Peter, Frankel Adam, Vedadi Masoud, Luo Minkui, Min Jinrong
Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5J 1L7, Canada.
Chemical Biology Program, Memorial Sloan-Kettering Cancer Center, New York, N.Y 10065, U.S.A.
Biochem J. 2016 Oct 1;473(19):3049-63. doi: 10.1042/BCJ20160537. Epub 2016 Aug 1.
PRMT6 is a type I protein arginine methyltransferase, generating the asymmetric dimethylarginine mark on proteins such as histone H3R2. Asymmetric dimethylation of histone H3R2 by PRMT6 acts as a repressive mark that antagonizes trimethylation of H3 lysine 4 by the MLL histone H3K4 methyltransferase. PRMT6 is overexpressed in several cancer types, including prostate, bladder and lung cancers; therefore, it is of great interest to develop potent and selective inhibitors for PRMT6. Here, we report the synthesis of a potent bisubstrate inhibitor GMS [6'-methyleneamine sinefungin, an analog of sinefungin (SNF)], and the crystal structures of human PRMT6 in complex, respectively, with S-adenosyl-L-homocysteine (SAH) and the bisubstrate inhibitor GMS that shed light on the significantly improved inhibition effect of GMS on methylation activity of PRMT6 compared with SAH and an S-adenosyl-L-methionine competitive methyltransferase inhibitor SNF. In addition, we also crystallized PRMT6 in complex with SAH and a short arginine-containing peptide. Based on the structural information here and available in the PDB database, we proposed a mechanism that can rationalize the distinctive arginine methylation product specificity of different types of arginine methyltransferases and pinpoint the structural determinant of such a specificity.
PRMT6是一种I型蛋白质精氨酸甲基转移酶,可在组蛋白H3R2等蛋白质上产生不对称二甲基精氨酸标记。PRMT6介导的组蛋白H3R2不对称二甲基化作为一种抑制性标记,可拮抗MLL组蛋白H3K4甲基转移酶对H3赖氨酸4的三甲基化作用。PRMT6在包括前列腺癌、膀胱癌和肺癌在内的多种癌症类型中过表达;因此,开发高效且选择性的PRMT6抑制剂具有重要意义。在此,我们报告了一种高效双底物抑制剂GMS [6'-亚甲基胺西奈芬净,西奈芬净(SNF)的类似物] 的合成,以及人PRMT6分别与S-腺苷-L-高半胱氨酸(SAH)和双底物抑制剂GMS形成复合物的晶体结构,这些结构揭示了与SAH和S-腺苷-L-甲硫氨酸竞争性甲基转移酶抑制剂SNF相比,GMS对PRMT6甲基化活性的抑制效果显著提高。此外,我们还使PRMT6与SAH和一个含精氨酸的短肽形成复合物并结晶。基于此处以及蛋白质数据库(PDB)中可用的结构信息,我们提出了一种机制,该机制可以解释不同类型精氨酸甲基转移酶独特的精氨酸甲基化产物特异性,并确定这种特异性的结构决定因素。